Hepatitis C Clinical Trial
— SUSTAINOfficial title:
A Multi-center, Randomized, Open Label, Controlled Study to Compare the Sustained Virological Response During Treatment With Neoral or Tacrolimus in Maintenance Liver Transplant Recipients Treated With Pegylated Interferon and Ribavirin for Recurrent Hepatitis C
This study will assess the rates of Sustained Virological Response following anti-viral therapy with Peg-Interferon plus Ribavirin in patients that have been liver transplanted with recurrent Hepatitis C and treated with Neoral or tacrolimus.
Status | Completed |
Enrollment | 92 |
Est. completion date | May 2013 |
Est. primary completion date | May 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion criteria: - Liver transplantation performed at least 6 months and up to 5 years prior randomization and due to HCV cirrhosis, with or without pre-transplant hepatocellular carcinoma (HCC) within Milan or UCSF criteria - Immunosuppresive regimen based on tacrolimus b.i.d.- (twice or once daily) for at least 6 months prior randomization - Diagnosis of HCV genotypes 1 or 4 infection prior to transplantationconfirmed at screening - Indication of treatment with Peg-IFN and ribavirin due to histological evidence of chronic HCV infection defined as a fibrosis stage equal or greater than 1 using the Ishak-Knodell scoring system (IK =1) in a liver biopsy performed at screening or up to 4 months prior to randomization. Exclusion criteria: - Serum creatinine >150 µmol/L (1.6 7 mg/dL) or eGFR < 50 ml/min (4-variable Modification of Diet in Renal Disease [MDRD Cockcroft-Gault formula]) - Multi-organ transplant recipients - Recent episode of steroid-treated acute rejection (AR) within 3 months prior to randomization, or >1 episode of steroid-treated AR in the last 6 months, or any number of steroid-resistant AR episodes in the last 6 months including evidence of chronic rejection or ductopenia - Evidence of conditions that could cause graft dysfunction other than HCV infection - Patients with signs of decompensated liver disease, defined as presence of ascites, variceal bleeding, encephalopathy or deteriorated hepatic synthetic function (albumin <3.5g/dL or, total direct bilirubin >1.5mg/dL or, INR >1.5) - Co-infection with HIV or Hepatitis B (defined as HBsAg-positive) at screening - Use of mTOR inhibitors (everolimus or sirolimus) in the 6 months prior to screening - Antiviral treatment for HCV administered at any time after liver transplantation - Patients on daily doses of corticosteroids higher than 5 mg/day - Patients with fibrosing cholestatic hepatitis - Patients with current diagnosis of malignancies, including lymphoproliferative disorders - Patients with platelet count <70,000/mm3 or neutrophiles <1,500/mm3 - History of HCC outside Milan criteria based on radiology or UCSF criteria based on analysis of the explant |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Belgium | Novartis Investigative Site | Bruxelles | |
Brazil | Novartis Investigative Site | Fortaleza | CE |
Brazil | Novartis Investigative Site | São Paulo | SP |
Canada | Novartis Investigative Site | Edmonton | Alberta |
Canada | Novartis Investigative Site | London | Ontario |
Canada | Novartis Investigative Site | Toronto | Ontario |
Canada | Novartis Investigative Site | Vancouver | British Columbia |
Canada | Novartis Investigative Site | Winnipeg | Manitoba |
Colombia | Novartis Investigative Site | Bogotá | Cundinamarca |
Colombia | Novartis Investigative Site | Bogotá | |
France | Novartis Investigative Site | Creteil | |
France | Novartis Investigative Site | Lyon Cedex 04 | |
France | Novartis Investigative Site | Montpellier | |
France | Novartis Investigative Site | Paris | |
France | Novartis Investigative Site | Toulouse Cedex 4 | |
France | Novartis Investigative Site | Villejuif | |
Germany | Novartis Investigative Site | Frankfurt | |
Germany | Novartis Investigative Site | Hamburg | |
Germany | Novartis Investigative Site | Mainz | |
Germany | Novartis Investigative Site | Muenchen | |
Italy | Novartis Investigative Site | Bologna | BO |
Italy | Novartis Investigative Site | Padova | PD |
Italy | Novartis Investigative Site | Udine | UD |
Korea, Republic of | Novartis Investigative Site | Seoul | Korea |
Korea, Republic of | Novartis Investigative Site | Seoul | Korea |
Korea, Republic of | Novartis Investigative Site | Seoul | Korea |
Korea, Republic of | Novartis Investigative Site | Seoul | Korea |
Russian Federation | Novartis Investigative Site | Moscow | |
Russian Federation | Novartis Investigative Site | Moscow | |
Spain | Novartis Investigative Site | Barcelona | Catalunya |
Spain | Novartis Investigative Site | Barcelona | Catalunya |
Spain | Novartis Investigative Site | Oviedo | Asturias |
Spain | Novartis Investigative Site | Santiago de Compostela | Galicia |
Spain | Novartis Investigative Site | Valladolid | Castilla y Leon |
Switzerland | Novartis Investigative Site | Zurich | |
United Kingdom | Novartis Investigative Site | Birmingham | |
United States | Novartis Investigative Site | Chapel Hill | North Carolina |
United States | Novartis Investigative Site | Gainesville | Florida |
United States | Novartis Investigative Site | Houston | Texas |
United States | Novartis Investigative Site | Houston | Texas |
United States | Novartis Investigative Site | Madison | Wisconsin |
United States | Novartis Investigative Site | Oklahoma City | Oklahoma |
United States | Novartis Investigative Site | Palo Alto | California |
United States | Novartis Investigative Site | Phoenix | Arizona |
United States | Novartis Investigative Site | San Francisco | California |
Lead Sponsor | Collaborator |
---|---|
Novartis Pharmaceuticals |
United States, Belgium, Brazil, Canada, Colombia, France, Germany, Italy, Korea, Republic of, Russian Federation, Spain, Switzerland, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants Sustained Virological Response (SVR) Following Treatment of Hepatitis C Virus (HCV) Infection With Peg-IFN and Ribavirin in Liver Transplanted Recipients on Maintenance Therapy With Neoral or Tacrolimus | The achievement of SVR, defined as HCV RNA below limit of detection at the end of AV treatment, 24 weeks after end of AV treatment (W24 post). A dichotomous variable (SVR achieved: Yes/No) was computed. A patient was classified as non-responder (SVR not achieved) if HCV RNA was detectable at the completion of antiviral treatment, at W24post, or at any time between W24 and completion of antiviral treatment. The HCV RNA detection limit was <15 IU/ml (<1.18 log IU/ml) | Week 24 | No |
Secondary | Number of Events of the Composite Endpoint of Biopsy Proven Acute Rejections (BPAR), Death or Graft Loss and of the Individual Components | Efficacy failure (biopsy proven acute rejection (BPAR), graft loss, or death | Week 80 | No |
Secondary | Number of Participants With Fibrosis Progression (Increase in Ishak-Knodell (IK) Score by at Least One Point From the Baseline) | Ishak-Knodell Score: 0=No fibrosis; 01=Fibrous expansion of some portal areas, with or without short fibrous septa; 02=Fibrous expansion of most portal areas, with or without short fibrous septa; 03=Fibrous expansion of most portal areas, with occasional portal to portal (P-P) bridging; 04=Fibrous expansion of portal areas, with marked bridging (portal to portal (P-P) as well as portal to central (P-C)); 05=Marked bridging (P-P and/or P-C) with occasional nodules (incomplete cirrhosis); 06=Cirrhosis, probable or definite, Participants showing an increase of Ishak Knodell fibrosis score by at least one level (increase of =1) | Week 80 | No |
Secondary | Number of Participants of Rapid Viral Response (RVR) | RVR defined as non-detectable HCV RNA 4 weeks after initiation of antiviral treatment. The HCV RNA detection limit was <15 IU/ml (<1.18 log IU/ml) | Week 4 | No |
Secondary | Number of Participants of Early Viral Response (EVR) | EVR defined as non-detectable HCV RNA or a =2 logs reduction of HCV RNA at 12 weeks after initiation of antiviral treatment. The HCV RNA detection limit was <15 IU/ml (<1.18 log IU/ml) | Week 12 | No |
Secondary | Number of Participants for the End of Treatment Response (ETR) | ETR defined as non-detectable HCV RNA at the completion of AV treatment. The HCV RNA detection limit was <15 IU/ml (<1.18 log IU/ml) | Week 80 | No |
Secondary | Number of Participants of True Non-responder Rate | Defined as failure to achieve at least a 2 log reduction of Hepatitis C virus (HCV) RNA. The HCV RNA detection limit was <15 IU/ml (<1.18 log IU/ml) | Week 80 | No |
Secondary | Number of Participants for Relapse Rate | Defined as reappearance of detectable Hepatitis C Virus (HCV) RNA at 24 weeks after completion of antiviral treatment when HCV RNA was undetectable at the end of treatment. The HCV RNA detection limit was <15 IU/ml (<1.18 log IU/ml) | Week 24 | No |
Secondary | Number of Participants With Dose Reduction or Discontinuation of Antiviral (AV) Therapy Due to Poor Tolerability at Any Time During the Study for Any Reason | Defined as number of patients with dose reduction or discontinuation of AV therapy due to poor tolerability | Week 80 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03686722 -
Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin
|
Phase 1 | |
Recruiting |
NCT04510246 -
Link Hepatitis C Notifications to Treatment in Tasmania
|
N/A | |
Completed |
NCT03413696 -
Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
|
||
Completed |
NCT03118674 -
Harvoni Treatment Porphyria Cutanea Tarda
|
Phase 2 | |
Completed |
NCT03109457 -
Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma
|
||
Completed |
NCT01458054 -
Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults
|
Phase 1 | |
Completed |
NCT03740230 -
An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
|
||
Completed |
NCT03426787 -
Helping Empower Liver and Kidney Patients
|
N/A | |
Completed |
NCT03627299 -
Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors
|
Phase 4 | |
Completed |
NCT00006301 -
Immune Response to Hepatitis C Virus
|
||
Active, not recruiting |
NCT03949764 -
The Kentucky Viral Hepatitis Treatment Study
|
Phase 4 | |
Completed |
NCT03365635 -
Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
|
Phase 4 | |
Recruiting |
NCT04405024 -
Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients
|
N/A | |
Completed |
NCT04525690 -
Improving Inpatient Screening for Hepatitis C
|
N/A | |
Completed |
NCT04033887 -
Evaluation Study of RDTs Detecting Antibodies Against HCV
|
||
Withdrawn |
NCT04546802 -
HepATocellular Cancer Hcv Therapy Study
|
Phase 3 | |
Active, not recruiting |
NCT02961426 -
Strategic Transformation of the Market of HCV Treatments
|
Phase 2/Phase 3 | |
Completed |
NCT02705534 -
Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
|
Phase 3 | |
Completed |
NCT02869776 -
Integrating HCV and HIV Screening During the Era of HIV Antigen Testing
|
N/A | |
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 |